PSMA PET imaging for evaluation of recurrent or persistent prostate cancer after primary prostate radiation. Differences between whole body magnetic resonance imaging (WB-MRI) and chest/abdomen/pelvis ...
An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...
Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT was superior to multiparametric MRI for primary locoregional staging of prostate cancer, according to results from a phase II ...
Figure 1. A 74-y-old man at initial staging with PSMA PET that demonstrates low uptake in primary tumor (A, arrowhead) and left pelvic side wall node (A, arrow). Bone scan was read as positive by 2 of ...
Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...
Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.
An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...
Source: Getty Images The molecular imaging modality detects metastases earlier and more accurately compared with conventional imaging and has ushered in a new era in metastasis-directed therapy. PSMA ...
Pretreatment 18F-PSMA-1007 PSMA PET/CT more accurately identifies prostate tumors compared with mpMRI. Fluorine-18 prostate-specific membrane antigen-1007 positron emission tomography/computed ...
SAULTE STE MARIE — MyMichigan Medical Center Sault has begun offering PSMA PET scans, providing men in the eastern Upper Peninsula with an advanced imaging tool to detect prostate cancer. The ...
An interview with Dr. Rohan Garje from Miami Cancer Institute in Miami, FL, lead author on "Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO ...
Good morning, good evening or afternoon, depending on where in the world you are. My name is Ky Williamson. I'm SVP of Investor Relations and Corporate Communication at Telix. Very pleased to welcome ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results